ArticleNature2023
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 137 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 2 pooled it
38.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 2 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Functional convergence amid taxonomic variability in gut microbiome-immune checkpoint inhibitor research: a bibliometric and mechanistic synthesis.Frontiers in immunology · 2026Pooled it
- The impact of antibiotic use in gastrointestinal tumors treated with immune checkpoint inhibitors: systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- Fecal microbiota transplantation for advanced non-small cell lung cancer with secondary PD-1 resistance efficacy prognostic factors and microbiome diversity analysis.Journal of translational medicine · 2026Trial
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.Cancer biology & therapy · 2026Review
- Association of gut microbiota composition and microbe-host interactions with response to chemoimmunotherapy in gastric cancer.Genes and immunity · 2026Article
- Response to pembrolizumab after progression on durvalumab in cholangiocarcinoma: a case report of immune checkpoint inhibitor switching.Clinical journal of gastroenterology · 2026Article
- Dendritic cell PD-L2 restrains intratumoral CD8bioRxiv : the preprint server for biology · 2026Article
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- Progressive Shifts in Oral Plaque Microbiota From Health to Coronary Artery Disease and Acute Myocardial Infarction.Cardiology research · 2026Article
- Toward a Dual-Axis Model of Microbiome Modulation in Cancer Immunotherapy: Pathobiont Elimination and Functional Ecosystem Restoration.Cellular and molecular bioengineering · 2026Article
- Review
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy.Chinese medical journal · 2026Review
- Review
- Harnessing the gut microbiota to enhance immune checkpoint inhibitor efficacy: from mechanistic insights to clinical translation.Molecular biology reports · 2026Review
- Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy.Cancer biology & medicine · 2026Review
- Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Decoding and exploiting intratumoral microbiota: from microenvironment modulation to clinical intervention.Molecular biology reports · 2026Review
- Metabolic and functional pathways of gut microbiota in patients with gastric cancer.Scientific reports · 2026Article
- Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026Review
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 2 institutions in 1 country.
Joon Seok Park *Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4001-6886
Francesca S Gazzaniga *Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Meng WuDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Amalia K LuthensDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2179-712X
Jacob GillisDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Wen ZhengDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Martin W LaFleurDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Sarah B JohnsonProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8936-0958
Golnaz MoradProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9460-618X
Elizabeth M ParkProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan ZhouProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephanie S WatowichProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1969-659X
Jennifer A WargoProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3438-7576
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. gordon_freeman@dfci.harvard.edu.ORCID 0000-0002-7210-5616
Dennis L KasperDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. dennis_kasper@hms.harvard.edu.ORCID 0000-0001-8808-5333
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. arlene_sharpe@hms.harvard.edu.ORCID 0000-0002-9736-2109
Harvard University · USThe University of Texas MD Anderson Cancer Center · US
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MPediatric Infectious Diseases Research TrainingT32HD055148 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI WESSELS, MICHAEL R · 2008 to 2018
$2.7MIdentifying gut bacterial molecules and mechanisms that promote an anti-tumor response to immunotherapyK22CA258960 · NCI · HARVARD MEDICAL SCHOOL · PI GAZZANIGA, FRANCESCA SMYLIE · 2022 to 2024
$559kRole of the Gut Microbiota in Regulating Responses to anti-PD-1 Cancer ImmunotherapyF32CA247072 · NCI · HARVARD MEDICAL SCHOOL · PI PARK, JOON SEOK · 2020 to 2022
$212kElucidating the role of gut, blood, and tumor microbiota in brain metastasisF32CA260769 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORAD, GOLNAZ · 2021 to 2023
$205kNCI NIH HHS 1F32CA260769-01NCI NIH HHS F32 CA247072NCI NIH HHS F32 CA260769NCI NIH HHS K22 CA258960NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA206963NIAID NIH HHS P01 AI056299NICHD NIH HHS T32 HD055148
Abstract
The gut microbiota is a crucial regulator of anti-tumour immunity during immune checkpoint inhibitor therapy. Several bacteria that promote an anti-tumour response to immune checkpoint inhibitors have been identified in mice
Indexed as
Drug Resistance, NeoplasmImmunotherapyMelanomaMicrobiotaAnimalsCell Adhesion Molecules, NeuronalDisease Models, AnimalDown-RegulationFecal Microbiota TransplantationGerm-Free LifeHumansImmune Checkpoint InhibitorsMiceProgrammed Cell Death 1 Ligand 2 ProteinProtein BindingT-LymphocytesCell Adhesion Molecules, NeuronalImmune Checkpoint InhibitorsPdcd1lg2 protein, mouseProgrammed Cell Death 1 Ligand 2 ProteinRgmb protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.